OPRD1 Antibody

Polyclonal Antibody

N-glycosylated. Ubiquitinated. A basal ubiquitination seems not to be related to degradation. Ubiquitination is increased upon formation of OPRM1:OPRD1 oligomers leading to proteasomal degradation; the ubiquitination is diminished by RTP4.

40/50 kDa

OPRD1

Liquid. PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

DOR-1 Polyclonal Antibody detects endogenous levels of DOR-1 protein.